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Human immune cell subsets develop in immunodeficient mice following reconstitution 
with human CD34+ hematopoietic stem cells. These “humanized” mice are useful mod-
els to study human immunology and human-tropic infections, autoimmunity, and cancer. 
However, some human immune cell subsets are unable to fully develop or acquire full 
functional capacity due to a lack of cross-reactivity of many growth factors and cytokines 
between species. Conventional dendritic cells (cDCs) in mice are categorized into cDC1, 
which mediate T helper (Th)1 and CD8+ T cell responses, and cDC2, which mediate 
Th2 and Th17 responses. The likely human equivalents are CD141+ DC and CD1c+ 
DC subsets for mouse cDC1 and cDC2, respectively, but the extent of any interspecies 
differences is poorly characterized. Here, we exploit the fact that human CD141+ DC 
and CD1c+ DC develop in humanized mice, to further explore their equivalency in vivo. 
Global transcriptome analysis of CD141+ DC and CD1c+ DC isolated from humanized 
mice demonstrated that they closely resemble those in human blood. Activation of DC 
subsets in vivo, with the TLR3 ligand poly I:C, and the TLR7/8 ligand R848 revealed 
that a core panel of genes consistent with DC maturation status were upregulated by 
both subsets. R848 specifically upregulated genes associated with Th17 responses by 
CD1c+ DC, while poly I:C upregulated IFN-λ genes specifically by CD141+ DC. MYCL 
expression, known to be essential for CD8 + T cell priming by mouse DC, was specifically 
induced in CD141+ DC after activation. Concomitantly, CD141+ DC were superior to 
CD1c+ DC in their ability to prime naïve antigen-specific CD8+ T cells. Thus, CD141+ 
DC and CD1c+ DC share a similar activation profiles in vivo but also have induce unique 
signatures that support specialized roles in CD8+ T cell priming and Th17 responses, 
respectively. In combination, these data demonstrate that humanized mice provide an 
attractive and tractable model to study human DC in vitro and in vivo.
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inTrODUcTiOn
Dendritic cells (DCs) are specialized antigen (Ag)-presenting 
cells that initiate and direct immune responses (1, 2). DC are a 
heterogenous cell population comprised of distinct subsets that 
harbor specialized capacity to drive specific immune responses. 
DC develop from CD34+ hematopoietic stem cells (HSC) in 
the bone marrow (BM) that develop into the common myeloid 
progenitor, giving rise to the more restricted macrophage/DC 
progenitor (MDP). The MDP can develop into monocytes, or 
the common DC progenitor (CDP). The CDP give rise to plas-
macytoid (p) DC and two “classical” or “conventional” (c) DC 
subsets now referred to as “cDC1” and “cDC2.” While surface 
marker expression has been the convention for characterization 
of conventional DC subsets, gene expression studies are redefin-
ing functional characteristics within these subsets (1, 3–5). pDCs 
are major producers of type-I IFN and are considered important 
for anti-viral immunity, the cDC1 and 2 subsets are critical for 
shaping adaptive immunity to intracellular and extracellular 
pathogens, respectively.
In mice, the cDC1 subset comprises the lymphoid resident 
CD8+ DC and the tissue resident CD103+ DC. These DCs 
require FLT3L and transcription factors IRF8, ID2, and Batf3 
for their development. cDC1 are required for priming protec-
tive CD8+ T  cell responses against cancer and for the efficacy 
of cancer immunotherapies (6). cDC1 produce high levels of 
IL-12p70, induce T helper (Th)-1 responses, and cross-present 
exogenous Ag for priming of CD8+ cytolytic T  cell responses 
(7–9). Hallmarks of these functions include the expression of 
chemokine receptor, XCR1, and adhesion molecule nectin-like 
protein 2 (Necl2/CADM1), both of which play important roles in 
CD8+ T cell priming (10–12). The presence of C-type lectin-like 
receptor, Clec9A, is essential for recognition and cross-priming 
of necrotic cell Ag, as is expression of TLR3, which enhances 
cross-priming and induces large amounts of IFNλ following 
ligation with agonists such as poly I:C (11, 13–15); and reviewed in 
Ref. (16). The human equivalent of cDC1 are defined as CD141+ 
(BDCA3)+ DC and share many similarities with mouse cDC1, 
including expression of XCR1, CADM1, Clec9A, and TLR3, 
Type III IFN production in response to TLR3 ligation, and cross-
presentation of Ag from necrotic cells (2). There is therefore a 
strong rationale to develop similar strategies to target the human 
cDC1 equivalent for new cancer immunotherapies (16).
The cDC2 subset is also referred to as CD11b+ DC in the 
mouse lymphoid and non-lymphoid tissues (1, 4). These DCs 
are FLT3L and IRF4 dependent and share significant overlap in 
phenotype with cells of the monocyte lineage (17). Monocyte-
derived DCs contribute to numerous DC niches throughout the 
body under inflamed conditions [reviewed in Ref. (18)], and 
are phenotypically distinct from cDC1 and cDC2 by a lack of 
expression of Flt3, and the zinc finger transcription factor zbtb46 
(19). cDC2 play a key role in driving adaptive immune responses 
to extracellular pathogens, owing to their capacity to promote 
Th2 and Th17 responses. The human equivalents of mouse 
cDC2 are defined as CD1c (BDCA-1)+ DC (2), and while there 
is evidence to suggest that they promote Th17 responses (20), 
they also produce high levels of IL-12, induce Th1 responses and 
can cross-present some forms of Ag to CD8+ T cells (21); in the 
absence of inducing T regulatory cells (22). Indeed CD1c+ DCs 
have also been trialed as vaccine candidates (23). Thus, there is 
currently no clear consensus as to whether targeting specific or 
multiple human DC subsets will be most beneficial for targeted 
immunotherapy (22).
Effective preclinical models to study human CD141+ DC and 
CD1c+ DC in vivo are needed in order to further understand fun-
damental human DC biology and evaluate new immunothera-
peutics. Transfer of human CD34+ HSC into immunodeficient 
mice lacking T, B, and NK cells leads to stable long-term engraft-
ment of human HSC and differentiation of human immune cell 
subsets. These “humanized”(hu) mice are emerging as a powerful 
tool to study the human immune system and are being increasingly 
used to model human-tropic infectious diseases, hematopoiesis, 
autoimmunity, and cancer and to evaluate new drugs, vaccines, 
and immunotherapeutics (24–26).
One of the current limitations of hu mouse models is the 
defective development and/or function of some human leu-
kocyte compartments, arising from a lack of cross-reactivity 
between mouse and human cytokines and growth factors 
(24–27). This is most notable within the monocyte/macrophage 
lineages, which require the addition of human cytokines to 
promote development and acquire functional capacity. Mouse 
Rag2−/−Il2rg−/− strains with human cytokine genes “knocked in” 
are under development, these strains accommodate enhanced 
monocyte/macrophage and NK cell lineage development (26). 
In contrast, we and others have shown that human CD141+ 
and CD1c+ DC subsets develop in the BM, spleen, and lungs 
following human CD34+ reconstitution in a number of immu-
nodeficient mouse strains, making this an attractive model 
to study human cDC function in  vivo (28–30). Although the 
CD141+ DC and CD1c+ DC that develop in these mice exhibit 
many of the phenotypic and functional characteristics of their 
human blood counterparts, the extent to which they recapitulate 
human DC functionally has not been fully defined. In this study, 
we examined the global transcriptome of the CD141+ DC and 
CD1c+ DC that develop and become activated in vivo in hu mice 
to establish the extent of their similarity with their human blood 
counterparts. We then used this model to identify early changes 
in gene expression associated with activation of human CD141+ 
DC and CD1c+ DC in  vivo. These data validate hu mice as a 
powerful model to study human DC and identify common and 
unique pathways associated with in vivo activation.
MaTerials anD MeThODs
generation of hu Mice and isolation of Dc
Cord blood was obtained with written informed consent from 
the Queensland Cord Blood Bank with approval from the Mater 
Adult Hospital Human Ethics Committee. CD34+ hematopoietic 
progenitor cells were isolated by density gradient enrichment fol-
lowed by a positive selection using a CD34+ isolation kit (Miltenyi 
Biotec) as previously described (30). NSG-A2 mice (stock no. 
014570) were purchased from Jackson Laboratories. 2–5-day-old 
NSG-A2 pups received 10  Gy total body irradiation 4  h prior 
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to intrahepatic injection of human CD34+ cells. Engraftment of 
human CD45+ cells was confirmed 10–12 weeks later, after which 
hu mice received 2 s.c. doses of human recombinant huFLT3-L 
(BioXcell) 4 days apart prior to experimentation. Engrafted mice 
were injected retro-orbitally with 50 µg poly IC (Invivogen) or 
20 µg R848 (Invivogen) alone or in combination and mice were 
euthanized 2  h later. This study was carried out in accordance 
with the recommendations of the Australian code for the care and 
use of animals for scientific purposes (8th Edition). The protocol 
was approved by the University of Queensland Animal Ethics 
Committee.
Flow cytometry
Single cell suspensions of BM, liver, lung, spleen, and peripheral 
blood from engrafted mice were blocked with rat and mouse 
serum then labeled with Live Dead® Aqua (Life Technologies), 
anti-mouse CD45 PerCP Cy5.5, anti-human CD45 APC Cy7, 
HLA DR PE Cy7, CD19/20 Pacific blue and either CD141 APC, 
CD123 PE (all from BioLegend), and CD1c FITC (Abcam) to 
identify DC, or CD3 Pacific blue, CD8 PE Cy7, CD14 APC (all 
from BioLegend), and CD4 FITC (BD Biosciences) for other 
leukocytes (Figure S1 in Supplementary Material). Absolute 
cell counts were determined by the addition of 5,000 Trucount 
beads (BD Biosciences) per tube. Data were acquired on a Cyan 
flow cytometer (Beckman Coulter) and analyzed using Flow Jo 
software (Tree star, version 8).
Dc isolation from hu Mice
Human DCs were enriched from single cell BM suspensions 
by first labeling with Ab specific for human CD3, CD14, CD19, 
CD20 (all from Beckman Coulter), CD34 (BD BioSciences), and 
mouse CD45 (BD BioSciences) and Ter119 (BioLegend) followed 
by depletion of bound cells using sheep anti-rat IgG Dynabeads 
(Invitrogen) as previously published (30). Cells were then labeled 
with Live Dead® aqua, anti-mouse CD45 PerCP Cy5.5, anti-
human CD45 APC Cy7, CD3/CD14/CD19/CD20 Pacific blue, 
HLA DR PE Cy7, CD123 PE or PerCP Cy5.5, CD1c FITC, and 
CD141 APC and sorted using a Moflo Astrios (Beckman Coulter) 
(Figure S2 in Supplementary Material).
gene expression analysis
Total RNA from purified DC subsets was prepared by resuspen-
ding between 1 × 105 and 1 × 106 cells in TRIzol Reagent (Life 
Technologies) followed by chloroform extraction and isopro-
panol precipitation. RNA quantity and integrity was measured 
using the Bioanalyzer RNA Nano chip (Agilent Technologies), 
with all RNA integrity numbers ranging between 8.4 and 9.7. 
cDNA was generated from 450 ng RNA and converted to cRNA 
using an Illumina TotalPrep RNA Amplification Kit (Ambion). 
A 14  h in  vitro transcription was performed. Amplified cRNA 
(750 ng) for each sample was hybridized onto HumanHT-12 v4 
Expression BeadChip Kit (Illumina) according to the manufac-
turer’s protocol and scanned on an Illumina BeadArray Reader 
(Illumina). Quality control, normalization, and log 2 transforma-
tion of the raw expression data were performed using the Lumi 
Bioconductor package (31) and integrated into the Stemformatics 
platform www.stemformatics.org (32) for visualization. Transcripts 
differentially expressed by CD141+ DC and CD1c+ DC were 
identified using ANOVA analysis with p value cut-off threshold 
of Bonferroni correction p < 0.01 and log(2) 3-fold difference. 
The data have been deposited in the GEO database, accession 
# GSE99666, and on Stemformatics http://www.stemformatics.
org/datasets/search?ds_id=6612. Publically available data sets 
and gene signatures for human DC subsets GSE35457 (17) were 
processed similarly for comparison.
cytokine chemokine and activation 
Marker assays
Dendritic cell subsets purified from hu mice were exposed to 
TLR adjuvants for 18 h in vitro, or cultured in media alone for 
18 h. Costimulatory molecule expression on the cell surface was 
quantified by flow cytometry. Culture supernatants and serum 
samples from the mice were analyzed for human cytokines using 
a LEGENDplex™ flow cytometry bead array kit (Biolegend). 
Human IFN-λ was measured by ELISA (R&D Systems).
cD8+ T cell Priming assays
HLA-A2+ DC subsets isolated from hu mice were pulsed with 
the HLA-A2-restricted MART-1 peptide, ELAGIGILTV (1 µM) 
in the presence of poly IC and R848 for 2 h at 37°C. Naïve CD8+ 
T  cells from autologous cord blood mononuclear cells were 
purified by negative selection using CD8+ T  cell isolation kit 
(Miltenyi Biotec). Peptide-pulsed DCs were cultured with naïve 
CD8+ T  cells in the presence of IL-2 (Hoffman-LaRoche) and 
T cell growth factor for 21 days. MART-1-specific CD8+ T cells 
were quantitated by flow cytometry using a MART-1/HLA-A2-
specific pentamer-APC (ProImmune), Live Dead® aqua, and 
anti-human CD19-Pacific blue, CD14-Pacific blue, CD3-PE, and 
CD8-FITC antibodies (BioLegend). Samples were acquired on 
a LSR Fortessa flow cytometer (BD Biosciences) and analyzed 
using Flow Jo software (Tree star, version 8). For polyfunctional 
T cell assays, the CD8+ T cell cultures were restimulated for 6 h in 
the presence of absence of MART-1 peptide (1 µM) with brefeldin 
A, GolgiStop, and anti-CD107a-FITC (BD Biosciences). Cells 
were then washed and labeled with anti-CD4 BV711, anti-CD8 
APC Cy7, and Live dead® followed by permeabilization (Cytofix/
Cytoperm; BD Biosciences) and stained with anti-TNFα APC, 
anti-IFNγ PE, and anti-IL-2 Alexa700. Samples were acquired 
on a LSR Fortessa cytometer (BD Biosciences) and analyzed 
using Flow Jo software (Tree star, version 8). Boolean gating was 
performed to measure the frequency of each response based on 
all possible functional combinations of IFNγ, TNFα, IL-2, and 
CD107a. The data were analyzed and graphed using Simplified 
Presentation of Incredibly Complex Evaluations (SPICE) soft-
ware, version 5.3.
resUlTs
hu Mouse cD141+ Dc and cD1c+ Dc  
are closely related to human Blood 
equivalents
Robust engraftment of human CD45+ cells was observed 
10–14 weeks after reconstitution of 2–5-day-old NSG-A2 pups 
FigUre 1 | Development of CD141+ and CD1c+ dendritic cell (DC) in hu mice. (a) Gating strategy used to define DC subsets in the bone marrow (BM) of hu 
mice. After gating on live singlet cells, DCs were defined as hu CD45+ HLA-DR+, CD19/20−, and CD1c+ or CD141+. (B) Frequency of human leukocytes, CD141+ 
DC and CD1c+ DC engrafted in the organs of NSG-A2 mice expressed as % mononuclear cells (huCD45) or as % hu CD45+ cells (CD141+ and CD1c+ DC).  
(c) Frequency of human leukocytes, CD141+ DC and CD1c+ DC expressed as absolute cell numbers per organ. BM data are quantitated per tibia and femur,  
and blood per ml.
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with human cord blood-derived CD34+ HSC (Figure  1A; 
Figure S1 in Supplementary Material). Human CD45+ cells were 
most prevalent in the spleen and liver, where they comprised 
57.34% + 17.97 (mean + SD, n = 9) and 67% + 21.45 (mean + SD, 
n = 5) of mononuclear cells, respectively. Human CD45+ cells 
comprised 39.88% + 15.66 (mean + SD, n = 5) of mononuclear 
cells in the BM and could also be detected in lower propor-
tions in the lungs and blood (Figure 1B). Human CD141+ and 
CD1c+ DC subsets were found in all organs examined, with the 
largest numbers residing in the BM compartment (Figure 1C). 
Human B cells, CD14+ monocytes, plasmacytoid DC, and CD4+ 
and CD8+ T  cells also developed in this model (Figure S1 in 
Supplementary Material). Thus, NSG-A2 mice support robust, 
multi-lineage development of human leukocytes, including 
CD141+ and CD1c+ DC.
We compared transcriptomes of BM-derived CD141+ and 
CD1c+ DC from hu mice with equivalents from human blood 
(17). We identified 316 genes that were significantly differen-
tially expressed (log-3 fold change, adjusted p < 0.01) between 
CD141+ and CD1c+ DC regardless of tissue source (Table S1 in 
Supplementary Material). Consistent with known DC functions, 
gene set enrichment analysis of these subsets ranked C-type 
lectins, endosomal TLR pathways, and the AIM2 inflammasome 
as most discriminating (Table S2 in Supplementary Material). 
FigUre 2 | Hu mouse CD141+ dendritic cell (DC) and CD1c+ DC subsets cluster with their human blood counterparts. Hierarchical Cluster (Pearson correlation) of 
gene expression data showing (a) differentially expressed genes with a log-3 fold change (lfc) over one with adjusted p value < 0.01. (B) Expression of genes known 
to be associated with CD141+ DC and CD1c+ DC. Sample groups are colored at the bottom of the sample tree by ClustDiff (CD1c+ green; CD141+ blue); host 
species (humanized mouse green; human cells blue) and treatment (R848 alone blue; Poly I:C green; Poly I:C + R848 combination pink; untreated orange). The 
color of expression scores is scaled by Z-score, per row.
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Hierarchical clustering analysis of the differentially expressed 
genes revealed clustering of hu mouse CD141+ DC with human 
blood CD141+ DC, and hu mouse CD1c+ DC with human blood 
CD1c+ DC (Figure 2A). In an unsupervised clustering approach, 
the first component of a principal component analysis was con-
cordant with batch, tissue, and species source (hu mice versus 
human blood). However, clustering of primary human CD141+ 
DC with hu mouse CD141+ DC, and CD1c+ DC across the two 
datasets with human peripheral blood monocytes was evident 
between the first and second principal components (Figure S3 in 
Supplementary Material).
Amongst the 156 genes preferentially expressed by hu 
mouse CD141+ DC and blood CD141+ DC were genes previ-
ously associated with this subset including CLEC9A, CADM1, 
ID2, BATF3, RAB7B, AIM2, BTLA, SEPT3, CLNK, and GSAM 
(Figure 2B; Table S1 in Supplementary Material). IRF8, TLR3, 
and XCR1 were also more highly expressed by CD141+ DC 
(Figure  2B; Figure S4 in Supplementary Material). Genes 
known to be expressed by the CD1c+ DC lineage, including 
IRF4, SIRPA, CLEC10A, FCGR2B, FCER1A, TLR5, and TLR7 
were amongst the 160 top ranked differentially expressed genes 
in hu mouse and human blood CD1c+ DC (Figure 2B; Table S1 in 
Supplementary Material). CD1c+ blood DCs have recently been 
subdivided into two subsets defined as “non-inflammatory” 
or “CD1c A”, defined by expression of FCER1A, CLEC10A, and 
FCGR2B; and “inflammatory” or “CD1c B” defined by expression 
of CD36 and CD163 along with inflammatory genes including 
CD14, S100A9, S100A8 (5). Hu mouse CD1c+ DC expressed 
much higher levels of the CD1c A non-inflammatory markers 
than hu mouse CD141+ DC, but also expressed the inflamma-
tory markers CD163, CD14, S100A9, and S100A8, which were 
further upregulated after activation (Figure S5 in Supplementary 
Material). These data indicate that the hu mouse CD1c+ DC 
isolated here likely contain both inflammatory and non-inflam-
matory CD1c+ DC subsets. Because CD1c+ DC have known 
overlapping features with monocytes (20), we used differential 
expression analysis to identify genes that CD1c+ DC and mono-
cytes co-express. More than 820 differentially expressed genes 
were identified by comparing hu mouse CD1c+ DC, blood 
CD1c+ DC, and blood monocyte subsets with CD141+ DC and 
pDC (log-3 fold change, adjusted p <  0.01, and Figure S6 in 
Supplementary Material). Genes shared between monocytes 
and CD1c+ DC included CSF1R, SIRPA, IL1B, NLRP3, CASP1, 
FCGR2A, and FCGR2B.
r848 and Poly i:c induce common gene 
expression Profiles in cD141+ Dc and 
cD1c+ Dc In Vivo
TLR expression and maturation by human DC are well char-
acterized in vitro but their responses in vivo are not. The TLR3 
ligand, poly I:C, and the TLR7/8 ligand, R848, have been used 
FigUre 3 | Changes in gene expression by hu mouse dendritic cells (DC) as a result stimulation with poly I:C and or R848 in vivo. Expression of CD1c+ DC and 
CD141+ DC genes following 2 h activation with poly I:C and/or R848 in vivo in hu mice. Boxes represent 25th–75th percentiles ± minimum and maximum values 
with line at the median from DC sorted from 2 to 3 individual mice. Expression of selected differentially expressed genes (a) upregulated by all TLR stimuli and  
(B) more highly expressed by R848 activated DC. Y-axis (normalized, log (2) expression).
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as adjuvants to activate human DC alone or in combination 
(21, 28, 33, 34). Because cytokines can be detected in mouse 
serum within 1 h of adjuvant injection (35), we chose a 2 h time 
point to investigate the early changes in gene expression associ-
ated with activation of BM derived CD141+ DC and CD1c+ 
DC in  vivo. A one-way AVONA analysis (adjusted p <  0.05) 
revealed differential expression of 408 genes as a result of activa-
tion. These genes were involved in immune signaling pathways 
including Tnfr2 signaling, IFNα/β signaling, Tnfr1 signaling 
(29% of pathway genes represented, p =  9.05E-04), canonical 
NF-κB pathway (17% of pathway genes represented, p = 0.027), 
RIG-I/MDA5, and TLR signaling (Figures  3A,B; Table S3 in 
Supplementary Material). Twenty five of these genes belong to 
a core set of NK-κB or IFN-stimulated genes (ISG) associated 
with DC maturation in both mouse and human irrespective of 
stimuli (Table S4 in Supplementary Material) (36). Most of the 
genes differentially expressed after activation were upregulated to 
similar degree by CD141+ DC and CD1c+ DC in response to all 
FigUre 4 | Expression of costimulatory molecules after activation of hu mouse CD141+ dendritic cells (DC) and CD1c+ DC. (a) Normalized log 2 expression of 
CD1c+ DC and CD141+ DC genes following 2 h activation with poly I:C and/or R848 in vivo in hu mice. Boxes represent 25th–75th percentiles ± minimum and 
maximum values with line at the median from DC sorted from 2 to 3 individual mice. (B) Cell surface protein expression of costimulatory molecules by purified DC 
subsets (0 h) and after 18 h culture in vitro in medium alone or with poly I:C + R848. Shown is the mean ± SEM fold upregulation of the mean fluorescence intensity 
of each costimulatory molecule relative to an isotype control.
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stimulatory conditions. These included TNFAIP3, TRAF1, IFIT1, 
ITIF2, ISG15, and OASL (Figure  3A). A small subset of genes 
were significantly upregulated by both CD141+ DC and CD1c+ 
DC in response to R848 alone or combined with poly I:C but were 
only marginally upregulated by poly I:C alone. These included 
immunoregulatory molecules LTA, NFIL3, CD274, and IGFB4 
(Figure 3B). Conversely, no genes were found to be significantly 
upregulated on both subsets activated with poly I:C that were not 
also upregulated by R848.
Poly I:C and R848 alone or combined induced expression of 
costimulatory molecule genes CD40, CD80, and CD83 to similar 
levels by both CD141+ DC and CD1c+ DC (Figure 4A). Gene 
expression correlated with increased protein expression of CD40, 
CD80, and CD83 on the surface of purified CD141+ DC and 
CD1c+ DC after in  vitro activation (Figure  4B). However, cell 
surface expression of CD80 was significantly higher on activated 
CD141+ DC compared to activated CD1c+ DC, and while CD83 
expression was also higher on activated CD141+ DC, this did not 
reach statistical significance. Similarly, chemokine genes CXCL9 
and CXCL10 were upregulated by both DC subsets following 
activation but only CXCL10 reached statistical significance 
(Figure  5A). Upregulation of CXCL9 and CXCL10 correlated 
with detectable levels of these chemokines in the serum of hu 
mice 2 h after activation (Figure 5B). In vitro, purified CD141+ 
DC were the main producers of CXCL9 while both subsets 
produced high levels of CXCL10 (Figure 5C). Collectively, these 
data highlight both common and distinct pathways of CD141+ 
DC and CD1c+ DC that are activated by R848, poly I:C, or the 
combination.
cD1c+ Dc Upregulate Th17 Promoting 
cytokines after activation In Vivo  
with r848
The mouse CD11b+ equivalents of CD1c+ DC promote Th17 
responses (20). Consistent with this, we found genes encoding the 
Th17-promoting cytokines IL1B and IL6 were upregulated by both 
BM derived DC subsets after activation, but levels expressed by 
activated CD1c+ DC were fourfold and eightfold higher than similarly 
activated CD141+ DC, respectively (Figure  6A). Importantly, 
expression of IL23A was 19-fold higher in CD1c+ DC activated 
with R848 alone or combined with poly I:C compared to similarly 
activated CD141+ DC. IL-1β, IL-6, and IL-23 were detectable in 
the serum of hu mice and although purified hu mouse CD1c+ DC 
produced higher amounts of these cytokines in  vitro compared 
to CD141+ DC, the levels did not reach statistical significance 
(Figures  6B,C). TNF and IL-12A were similarly upregulated 
by in vivo activated CD141+ DC and CD1c+ DC with cytokines 
detectable in the serum. Higher levels of TNF and IL-12p70 were 
produced by in vitro cultured CD1c+ DC compared with CD141+ 
DC, although this did not reach statistical significance (Figure 6C).
cD141+ Dc Upregulate Type iii iFn after 
activation In Vivo with Poly i:c
CD141+ DC have previously been shown to produce IFNα after 
poly I:C activation in vivo (28). Here, we found genes for IFNα 
subtypes IFNA2, IFNA7, and IFNA21 were upregulated to a similar 
degree by both subsets, most notably in response to R848 alone or 
combined with poly I:C, while genes encoding most other IFNα 
FigUre 5 | Expression of chemokines CXCL9 and CXCL10 by hu mouse CD141+ dendritic cells (DC) and CD1c+ DC. (a) Normalized log 2 expression of CD1c+ 
DC and CD141+ DC genes following 2 h activation with poly I:C and/or R848 in vivo in hu mice. Boxes represent 25th–75th percentiles ± minimum and maximum 
values with line at the median from DC sorted from 2 to 3 individual mice (B) Chemokine protein levels in the serum of hu mice 2 h after activation. (c) Production of 
chemokine protein by purified hu mouse DC 18 h after activation in vitro, versus control [cultured in medium alone in vitro (cont)].
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subtypes were below detectable levels in both BM-derived DC 
subsets (Figure 7A). Although large amounts of IFNα were detec-
table in the serum of mice treated with R848 and R848 + poly I:C, 
no IFNα was detected in the serum of mice treated with poly 
I:C alone (Figure 7B). Moreover, IFNα was not detectable in the 
supernatants of purified CD141+ or CD1c+ DC activated in vitro 
(data not shown). IFNB1 was upregulated by both subsets in 
response to all stimuli. CD141+ DC are known to produce large 
amounts of IFNλ in response to poly I:C (14) and consistent with 
this, IFNλ genes IL28A, IL28B, and IL29 were expressed 13-, 
17-, and 8-fold higher by poly I:C + R848-activated CD141+ DC 
compared to similarly activated CD1c+ DC (Figure  7A). This 
correlated with detection of IFNλ in the serum and in the super-
natants of purified CD141+ DC activated in  vitro (Figure  7C). 
These data confirm that CD141+ DC are major producers of IFNλ 
in vivo.
cD141+ Dc Upregulate MYCL after 
activation and Prime naïve cD8+ T cells
MYCL is required for optimal CD8+ T cell priming by mouse DC 
(37) and was expressed at 10-fold higher levels by CD141+ DC 
FigUre 6 | Expression of inflammatory cytokines by hu mouse CD141+ dendritic cells (DC) and CD1c+ DC. (a) Gene expression levels 2 h after activation of DC 
subsets in vivo. Data are presented as 25th–75th percentiles ± minimum and maximum values with line at the median of normalized log 2 gene expression by DC 
subsets sorted from 2 to 3 individual mice. (B) Cytokine levels in the serum of hu mice 2 h after activation. (c) Production of cytokines by purified hu mouse DC 18 h 
after activation in vitro, versus control [cultured in medium alone in vitro (cont)].
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activated with either poly I:C or R848 compared to similarly acti-
vated CD1c+ DC (Figure 8A). This suggested an enhanced capac-
ity for activated CD141+ DC to prime naïve CD8+ T cells that may 
be independent of their enhanced capacity for cross-presentation. 
To address the potential for enhanced priming ability by activated 
CD141+ DC, we purified human HLA-A2+ DC subsets from hu 
mice and pulsed them with the HLA-A2-restricted peptide from 
the melanoma Ag MART-1 after activation with combined poly 
I:C + R848. Peptide pulsed, activated CD141+ DC and CD1c+ DC 
were used to prime autologous, naïve cord blood CD8+ T cells. 
CD141+ DC primed a significantly higher percentage of MART-
1-specific CD8+ T  cells compared to CD1c+ DC (Figure  8B). 
However, there was no difference in the polyfunctional capacity 
of the T cells by either subset, as measured by production of effec-
tor molecules IFNγ, TNF, IL-2, and CD107a (Figure 8C).
DiscUssiOn
In this study, we demonstrate that hu mice are a robust model 
to study human CD141+ DC and CD1c+ DC development and 
function in vivo. Using global transcriptome analysis, we showed 
that CD141+ DC and CD1c+ DC developing in the BM of hu 
mice closely resembled those of their human blood counterparts. 
Moreover, we have mapped the early genetic changes that human 
CD141+ DC and CD1c+ DC undergo following activation in vivo. 
Our data show that when activated with poly I:C or R848, alone or 
combined, both subsets undergo similar initial genetic program-
ing events that include upregulation of a core set of genes broadly 
associated with DC maturation, in addition to upregulation of 
a more select number of subset-specific genes that confer func-
tional specificity.
We used publically available datasets for human blood DC 
and monocyte subsets to establish the degree of similarity with 
human DC subsets developing in hu mouse. We identified a 
signature of 156 preferentially expressed genes that were shared 
by blood and hu mouse CD141+ DC regardless of their activa-
tion status, including many of the known hallmark genes such as 
CLEC9A, CADM1, ID2, and BATF3 (11, 38, 39). Other hallmark 
genes including IRF8, TLR3, and XCR1 were also confirmed 
to be expressed by hu mouse CD141+ DC but fell outside the 
stringent statistical threshold, either because the genes changed 
after activation or due to low probe hybridization (33, 40–42). 
FigUre 7 | Expression of type I and type III IFN by hu mouse CD141+ dendritic cells (DC) and CD1c+ DC. (a) Expression of selected IFN genes by hu mice DC 2 h 
after activation in vivo. Data are represented as min–max values (line at mean) from 2 to 3 replicates for each condition. (B) Human IFNα and IFNλ in the serum of hu 
mice 2 h after activation. (c) IFNλ production by DC subsets purified from hu mice after stimulation with poly I:C and R848 in vitro, versus control [cultured in 
medium alone in vitro (cont)].
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These data demonstrate close genetic similarity between CD141+ 
DC developing in hu mice with those in human blood, providing 
further validation of hu mice as a powerful model to study human 
CD141+ DC biology. A recent study comparing the transcrip-
tomes of human DC subsets in blood, spleen, thymus, tonsil, BM, 
and cord blood demonstrated that CD141+ DC in these organs 
are most strongly defined by ontogeny and are less influenced 
by their tissue environment (43). Cross presentation primarily 
by conventional CD11c+ DC in the BM has been demonstrated, 
which primed naïve CD4+ and CD8+ T cells and resulted in cyto-
toxic T cells; demonstrating also functional similarity (44, 45). 
Therefore, hu mice are likely to be a useful model that more 
generally represents the CD141+ DC lineage across the lympho-
hematopoietic system. FLT3L treatment was used to expand the 
number of human DC in vivo from humanized mice as per our 
previous published studies (30). Expansion of DC is performed 
by two injections of FLT3L 4  days apart prior to experimental 
treatments. This prior study demonstrated that the ratio of CD1c+ 
DC to CD141+ DC in humanized mice becomes more like that 
found in human blood (~8:1), and human spleens (~4:1) after 
FLT3L injections, and FLT3L-expanded DCs were functionally 
similar to their human DC counterparts. Thus, the abundance of 
CD141+ DC in hu mice, particularly after FLT3L administration, 
provides an excellent means of overcoming the lack of signatures 
obtained from published datasets (43). Indeed, we were able to 
recover sufficient cell numbers from the BM and RNA to obviate 
the need for amplification prior to hybridization. Although the 
transcriptional signatures of CD141+ DC in human skin and 
lung share similar ontogeny, they are also heavily influenced by 
tissue-derived signals (17, 43). CD141+ DC develop in the lung 
and liver of hu mice, but whether they are representative of those 
in non-lymphohematopoietic tissues remains to be determined.
CD1c+ DC in blood and hu mice shared preferential expres-
sion of 160 genes that included known hallmark genes associated 
with this subset such as IRF4, SIRPA, CLEC10A, FCGR2B, and 
FCER1A. However, consistent with other reports (17, 20), there 
FigUre 8 | Increased expression of MYCL and CD8+ T cell priming capacity by activated CD141+ dendritic cells (DC). (a) Gene expression of MYCL 2 h after 
activation of DC subsets in vivo. (B) Priming of autologous naïve MART-1-specific CD8+ T cells by CD141+ DC and CD1c+ DC, shown as the percentage of CD8+ 
T cells staining for MART-1-specific pentamer. (c) Effector function of MART-1-specific CD8+ T cells primed by CD141+ DC and CD1c+ DC expressed as % of 
antigen (Ag)-specific cells producing effector molecules CD107a, TNF, IFNγ, or IL-2 (left) and % of Ag-specific CD8+ T cells simultaneously producing one or more 
effector molecules (right).
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were very few genes that were uniquely expressed by CD1c+ 
DC and many of the genes preferentially expressed by CD1c+ 
DC were shared with monocytes, suggesting overlapping func-
tions between these two cell lineages. Although the degree of 
functional heterogeneity within the CD1c+ DC populations is 
unclear, single-cell RNA profiling has segregated blood CD1c+ 
DC into two further subtypes that are distinguished by expression 
of inflammatory genes (5). Genes discriminating both CD1c+ DC 
subsets were enriched in hu mouse CD1c+ DC and genes asso-
ciated with the inflammatory CD1c+ DC subtype were further 
upregulated after activation in our dataset, suggesting that both 
subsets develop in hu mice. Thus, we conclude that the CD1c+ DC 
developing in hu mice are closely related to those in human blood 
and like CD141+ DC, may also be representative of this subset 
across the lymphohematopoietic system (43). However, as CD1c+ 
DC in non-lymphohematopoietic tissues appear to be even more 
influenced by their microenvironment than other DC subsets, the 
CD1c+ DC developing in hu mouse BM may not fully reflect the 
properties of these cells in other tissues.
Our study provides the first insights into the early genetic 
programing events that occur following activation of CD141+ 
DC and CD1c+ DC in vivo. We demonstrated a concordant gene 
expression pattern that occurred in both subsets in response to all 
stimuli. These genes were largely associated with ISG and NFκb 
signaling and many were found to belong to a core set of genes 
that are commonly induced following activation of mouse DC 
subsets and human DC cultured in vitro (34, 36). Our data extend 
these observations to demonstrate that upregulation of this core 
set of genes associated with DC maturation is also conserved in 
in  vivo activated human CD141+ DC and CD1c+ DC, further 
validating the functional integrity of hu mouse DC. With the 
exception of a select panel of immunoregulatory genes that were 
more highly expressed following activation with R848, most genes 
upregulated on both DC subsets were induced to a similar degree 
by either poly I:C or R848 activation. Moreover, the combination 
of R848 and poly I:C did not further augment gene expression. 
Similar observations have been made on monocyte-derived DC, 
where the small proportion of genes specifically upregulated by 
combinatorial stimuli are only evident at later time points of 8 h 
post activation (46).
Only a small number of genes were found to be differentially 
regulated by CD141+ DC and CD1c+ DC in response to activa-
tors. Notably, activated CD1c+ DC expressed higher levels of 
IL1B, IL6, and IL23A compared to similarly activated CD141+ 
DC. CD1c+ DC purified from hu mice and activated in  vitro 
produced higher levels of these cytokines compared to CD141+ 
DC, although this did not reach statistical significance. These 
observations support a role for CD1c+ DC in promoting Th17 
responses similar to what has been reported for their mouse 
counterparts and human lung resident CD1c+ DC (20). Our data 
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extend this to CD1c+ DC in the lymphohematopoietic system, 
suggesting that this is a conserved specialist function of this 
lineage that occurs within 2  h of activation. CD141+ DC and 
not CD1c+ DC upregulated MYCL following activation with 
poly I:C or R848 in  vivo. Since MYCL has been shown to be 
essential for optimal CD8+ T cell priming by mouse DC (37) this 
suggests a similar function for human CD141+ DC. The higher 
expression of CD80, CD83, and CXCL9 by CD141+ DC is also 
consistent with a role in CD8+ T cell priming. Although peptide 
pulsed CD141+ DC were able to more efficiently expand naïve 
autologous Ag-specific CD8+ T  cells compared to CD1c+ DC 
in vitro, the overall quality of the T cells in terms of cytokine 
polyfunctionality was similar and the role of individual human 
DC subsets in the induction of effector CD8+ T cell responses 
requires further clarification.
CD141+ DC were previously identified as being major pro-
ducers of IFNα in response to poly I:C (28), however, our data did 
not provide evidence to support this in vivo. Although transcripts 
for a few IFN subtypes were found to be upregulated by both 
DC subsets and high levels of IFNα were detectable in the serum 
of hu mice after activation with R848, only IFNB1 was found to 
be induced by poly I:C. In mice, most of the IFNα produced in 
response to poly I:C arises from non-hematopoietic cells (35), 
which is consistent with our hu mice, where the only human 
cells present are of hematopoietic origin. Type I IFN induction 
in DC occurs via an initial induction phase within 1 h followed 
by a feedback loop leading to a secondary amplification phase 
(47). Our data suggest that poly I:C induces IFNβ but not IFNα 
subtypes by CD141+ DC and CD1c+ DC, whereas R848 induces 
both IFNβ and IFNα during the first phase of induction. The 
production of IFNα by CD141+ DC observed by Meixlsperger 
et al. was measured at later time points, suggesting production 
during the secondary amplification phase. In contrast, increased 
expression of Type III IFN (IFNλ) genes, IL28A, IL28B, and IL29 
was evident in CD141+ DC activated with poly I:C alone or in 
combination with R848. This correlated with high levels of IFNλ 
secretion by this subset in vitro and is consistent with previous 
reports that CD141+ DC are major producers of IFNλ in response 
to poly I:C (14). Collectively our data support the use of hu mice 
as both a practical and valuable tool for characterizing human 
lymphohematopoietic CD141+ DC and CD1c+ DC function 
in vivo.
eThics sTaTeMenT
Cord blood was obtained with written informed consent from 
the Queensland Cord Blood Bank with approval from the Mater 
Adult Hospital Human Ethics Committee. This study was carried 
out in accordance with the recommendations of the Australian 
code for the care and use of animals for scientific purposes 
(8th Edition). The protocol was approved by the University of 
Queensland Animal Ethics Committee.
aUThOr cOnTriBUTiOns
YM, IR, and OH designed and performed the hu mouse experi-
ments and analyzed the data. IV and CW analyzed and interpreted 
the bioinformatics data and wrote the manuscript. JM and YW 
designed, analyzed and interpreted data, KR conceptualized and 
designed the project, analyzed and interpreted data, and wrote 
the manuscript.
acKnOWleDgMenTs
We thank Robyn Rodwell and staff of the Queensland Cord Blood 
Bank at the Mater Hospital, Brisbane, a member of AusCord 
the Australian National Cord Blood Collection and Banking 
Network, for provision of cord blood samples for the study, and 
staff at the Translational Research Institute flow core facility for 
their expert technical assistance.
FUnDing
The project was funded by the National Health and Medical 
Research Council of Australia project grants 604306 and 1078987 
and Career Development Fellowships 1008986 (KR) and 1131732 
(JM), Australian Research Council Future Fellowship (CW), and 
by the Mater Foundation, Brisbane Australia. The Translational 
Research Institute is supported by a grant from the Australian 
Government.
sUPPleMenTarY MaTerial
The Supplementary Material for this article can be found online at 
http://www.frontiersin.org/article/10.3389/fimmu.2017.01419/
full#supplementary-material.
TaBle s1 | List of genes differentially expressed by CD141+ dendritic cell (DC) 
and CD1c+ DC in hu mice and human blood.
TaBle s2 | Reactome enrichment: list of pathways significantly enriched in hu 
mouse and human blood dendritic cell.
TaBle s3 | Reactome enrichment analysis of differentially expressed genes in 
dendritic cell stimulated with poly IC, R848, and the combination in vivo.
TaBle s4 | Differentially expressed genes in dendritic cell (DC) stimulated as a 
result of activation in vivo. Highlighted in yellow are genes previously identified as 
being upregulated in DC after activation.
reFerences
1. Mildner A, Jung S. Development and function of dendritic cell subsets. 
Immunity (2014) 40(5):642–56. doi:10.1016/j.immuni.2014.04.016 
2. O’Keeffe M, Mok WH, Radford KJ. Human dendritic cell subsets and function 
in health and disease. Cell Mol Life Sci (2015) 72(22):4309–25. doi:10.1007/
s00018-015-2005-0 
3. Guilliams M, Ginhoux F, Jakubzick C, Naik SH, Onai N, Schraml BU, et al. 
Dendritic cells, monocytes and macrophages: a unified nomenclature 
based on ontogeny. Nat Rev Immunol (2014) 14(8):571–8. doi:10.1038/ 
nri3712 
4. Guilliams M, van de Laar L. A Hitchhiker’s guide to myeloid cell subsets: prac-
tical implementation of a novel mononuclear phagocyte classification system. 
Front Immunol (2015) 6:406. doi:10.3389/fimmu.2015.00406 
5. Villani AC, Satija R, Reynolds G, Sarkizova S, Shekhar K, Fletcher J, et  al. 
Single-cell RNA-seq reveals new types of human blood dendritic cells, 
monocytes, and progenitors. Science (2017) 356(6335):eaah4573. doi:10.1126/
science.aah4573 
13
Minoda et al. Transcriptome of In Vivo Activated Human DC
Frontiers in Immunology | www.frontiersin.org October 2017 | Volume 8 | Article 1419
6. Gardner A, Ruffell B. Dendritic cells and cancer immunity. Trends Immunol 
(2016) 37(12):855–65. doi:10.1016/j.it.2016.09.006 
7. Soares H, Waechter H, Glaichenhaus N, Mougneau E, Yagita H, Mizenina O, 
et al. A subset of dendritic cells induces CD4+ T cells to produce IFN-gamma 
by an IL-12-independent but CD70-dependent mechanism in vivo. J Exp Med 
(2007) 204(5):1095–106. doi:10.1084/jem.20070176 
8. Wieckowski E, Chatta GS, Mailliard RM, Gooding W, Palucka K, Banchereau J, 
et al. Type-1 polarized dendritic cells loaded with apoptotic prostate cancer cells 
are potent inducers of CD8(+) T cells against prostate cancer cells and defined 
prostate cancer-specific epitopes. Prostate (2011) 71(2):125–33. doi:10.1002/ 
pros.21228 
9. Amigorena S. Helping the help for CD8+ T  cell responses. Cell (2015) 
162(6):1210–2. doi:10.1016/j.cell.2015.08.051 
10. Contreras V, Urien C, Guiton R, Alexandre Y, Vu Manh TP, Andrieu T, et al. 
Existence of CD8alpha-like dendritic cells with a conserved functional spe-
cialization and a common molecular signature in distant mammalian species. 
J Immunol (2010) 185(6):3313–25. doi:10.4049/jimmunol.1000824 
11. Poulin LF, Salio M, Griessinger E, Anjos-Afonso F, Craciun L, Chen JL, et al. 
Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equiv-
alents of mouse CD8alpha+ dendritic cells. J Exp Med (2010) 207(6):1261–71. 
doi:10.1084/jem.20092618 
12. Hartung E, Becker M, Bachem A, Reeg N, Jakel A, Hutloff A, et al. Induction 
of potent CD8 T  cell cytotoxicity by specific targeting of antigen to cross- 
presenting dendritic cells in  vivo via murine or human XCR1. J Immunol 
(2015) 194(3):1069–79. doi:10.4049/jimmunol.1401903 
13. Sancho D, Joffre OP, Keller AM, Rogers NC, Martinez D, Hernanz-Falcon P, 
et  al. Identification of a dendritic cell receptor that couples sensing of 
necrosis to immunity. Nature (2009) 458(7240):899–903. doi:10.1038/
nature07750 
14. Lauterbach H, Bathke B, Gilles S, Traidl-Hoffmann C, Luber CA, Fejer G, 
et al. Mouse CD8alpha+ DCs and human BDCA3+ DCs are major producers 
of IFN-lambda in response to poly IC. J Exp Med (2010) 207(12):2703–17. 
doi:10.1084/jem.20092720 
15. Ahrens S, Zelenay S, Sancho D, Hanc P, Kjaer S, Feest C, et al. F-actin is an 
evolutionarily conserved damage-associated molecular pattern recognized 
by DNGR-1, a receptor for dead cells. Immunity (2012) 36(4):635–45. 
doi:10.1016/j.immuni.2012.03.008 
16. Tullett KM, Lahoud MH, Radford KJ. Harnessing human cross-presenting 
CLEC9A(+)XCR1(+) dendritic cells for immunotherapy. Front Immunol 
(2014) 5:239. doi:10.3389/fimmu.2014.00239 
17. Haniffa M, Shin A, Bigley V, McGovern N, Teo P, See P, et al. Human tissues 
contain CD141(hi) cross-presenting dendritic cells with functional homol-
ogy to mouse CD103(+) nonlymphoid dendritic cells. Immunity (2012) 
37(1):60–73. doi:10.1016/j.immuni.2012.04.012 
18. Merad M, Sathe P, Helft J, Miller J, Mortha A. The dendritic cell lineage: 
ontogeny and function of dendritic cells and their subsets in the steady state 
and the inflamed setting. Annu Rev Immunol (2013) 31:563–604. doi:10.1146/
annurev-immunol-020711-074950 
19. Karsunky H, Merad M, Cozzio A, Weissman IL, Manz MG. Flt3 ligand regula-
tes dendritic cell development from Flt3+ lymphoid and myeloid-committed 
progenitors to Flt3+ dendritic cells in vivo. J Exp Med (2003) 198(2):305–13. 
doi:10.1084/jem.20030323 
20. Schlitzer A, McGovern N, Teo P, Zelante T, Atarashi K, Low D, et al. IRF4 
transcription factor-dependent CD11b+ dendritic cells in human and mouse 
control mucosal IL-17 cytokine responses. Immunity (2013) 38(5):970–83. 
doi:10.1016/j.immuni.2013.04.011 
21. Nizzoli G, Krietsch J, Weick A, Steinfelder S, Facciotti F, Gruarin P, et  al. 
Human CD1c+ dendritic cells secrete high levels of IL-12 and potently 
prime cytotoxic T-cell responses. Blood (2013) 122(6):932–42. doi:10.1182/
blood-2013-04-495424 
22. Sittig SP, Bakdash G, Weiden J, Skold AE, Tel J, Figdor CG, et  al. A com-
parative study of the T  cell stimulatory and polarizing capacity of human 
primary blood dendritic cell subsets. Mediators Inflamm (2016) 2016:3605643. 
doi:10.1155/2016/3605643 
23. Prue RL, Vari F, Radford KJ, Tong H, Hardy MY, D’Rozario R, et  al.  
A phase I clinical trial of CD1c (BDCA-1)+ dendritic cells pulsed with 
HLA-A*0201 peptides for immunotherapy of metastatic hormone refrac-
tory prostate cancer. J Immunother (2015) 38(2):71–6. doi:10.1097/CJI. 
0000000000000063 
24. Shultz LD, Brehm MA, Garcia-Martinez JV, Greiner DL. Humanized mice 
for immune system investigation: progress, promise and challenges. Nat Rev 
Immunol (2012) 12(11):786–98. doi:10.1038/nri3311 
25. Rongvaux A, Willinger T, Martinek J, Strowig T, Gearty SV, Teichmann LL, 
et  al. Development and function of human innate immune cells in a 
humanized mouse model. Nat Biotechnol (2014) 32(4):364–72. doi:10.1038/
nbt.2858 
26. Saito Y, Ellegast JM, Manz MG. Generation of humanized mice for 
analysis of human dendritic cells. Methods Mol Biol (2016) 1423:309–20. 
doi:10.1007/978-1-4939-3606-9_22 
27. Lux A, Nimmerjahn F. Of mice and men: the need for humanized mouse 
models to study human IgG activity in vivo. J Clin Immunol (2013) 33(Suppl 1): 
S4–8. doi:10.1007/s10875-012-9782-0 
28. Meixlsperger S, Leung CS, Ramer PC, Pack M, Vanoaica LD, Breton G, et al. 
CD141+ dendritic cells produce prominent amounts of IFN-alpha after 
dsRNA recognition and can be targeted via DEC-205 in humanized mice. 
Blood (2013) 121:5034–44. doi:10.1182/blood-2012-12-473413 
29. Yu CI, Becker C, Wang Y, Marches F, Helft J, Leboeuf M, et  al. Human 
CD1c+ dendritic cells drive the differentiation of CD103+ CD8+ mucosal 
effector T  cells via the cytokine TGF-beta. Immunity (2013) 38(4):818–30. 
doi:10.1016/j.immuni.2013.03.004 
30. Ding Y, Wilkinson A, Idris A, Fancke B, O’Keeffe M, Khalil D, et al. FLT3-ligand 
treatment of humanized mice results in the generation of large numbers of 
CD141+ and CD1c+ dendritic cells in vivo. J Immunol (2014) 192(4):1982–9. 
doi:10.4049/jimmunol.1302391 
31. Lin SM, Du P, Huber W, Kibbe WA. Model-based variance-stabilizing trans-
formation for Illumina microarray data. Nucleic Acids Res (2008) 36(2):e11. 
doi:10.1093/nar/gkm1075 
32. Wells CA, Mosbergen R, Korn O, Choi J, Seidenman N, Matigian NA, et al. 
Stemformatics: visualisation and sharing of stem cell gene expression. Stem 
Cell Res (2013) 10(3):387–95. doi:10.1016/j.scr.2012.12.003 
33. Jongbloed SL, Kassianos AJ, McDonald KJ, Clark GJ, Ju X, Angel CE, et al. 
Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid 
DC subset that cross-presents necrotic cell antigens. J Exp Med (2010) 207(6): 
1247–60. doi:10.1084/jem.20092140 
34. Balan S, Ollion V, Colletti N, Chelbi R, Montanana-Sanchis F, Liu H, et al. 
Human XCR1+ dendritic cells derived in vitro from CD34+ progenitors closely 
resemble blood dendritic cells, including their adjuvant responsiveness, con-
trary to monocyte-derived dendritic cells. J Immunol (2014) 193(4):1622–35. 
doi:10.4049/jimmunol.1401243 
35. Longhi MP, Trumpfheller C, Idoyaga J, Caskey M, Matos I, Kluger C, et al. 
Dendritic cells require a systemic type I interferon response to mature and 
induce CD4+ Th1 immunity with poly IC as adjuvant. J Exp Med (2009) 
206(7):1589–602. doi:10.1084/jem.20090247 
36. Manh TP, Alexandre Y, Baranek T, Crozat K, Dalod M. Plasmacytoid, con-
ventional, and monocyte-derived dendritic cells undergo a profound and 
convergent genetic reprogramming during their maturation. Eur J Immunol 
(2013) 43(7):1706–15. doi:10.1002/eji.201243106 
37. Kc W, Satpathy AT, Rapaport AS, Briseno CG, Wu X, Albring JC, et al. L-Myc 
expression by dendritic cells is required for optimal T-cell priming. Nature 
(2014) 507(7491):243–7. doi:10.1038/nature12967 
38. Hildner K, Edelson BT, Purtha WE, Diamond M, Matsushita H, Kohyama M, 
et al. Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in 
cytotoxic T cell immunity. Science (2008) 322(5904):1097–100. doi:10.1126/
science.1164206 
39. Zhang JG, Czabotar PE, Policheni AN, Caminschi I, Wan SS, Kitsoulis S, 
et al. The dendritic cell receptor Clec9A binds damaged cells via exposed 
actin filaments. Immunity (2012) 36(4):646–57. doi:10.1016/j.immuni. 
2012.03.009 
40. Dorner BG, Dorner MB, Zhou X, Opitz C, Mora A, Guttler S, et al. Selective 
expression of the chemokine receptor XCR1 on cross-presenting dendritic cells 
determines cooperation with CD8+ T cells. Immunity (2009) 31(5):823–33. 
doi:10.1016/j.immuni.2009.08.027 
41. Crozat K, Guiton R, Contreras V, Feuillet V, Dutertre CA, Ventre E, et  al. 
The XC chemokine receptor 1 is a conserved selective marker of mammalian 
cells homologous to mouse CD8alpha+ dendritic cells. J Exp Med (2010) 
207(6):1283–92. doi:10.1084/jem.20100223 
42. Sichien D, Scott CL, Martens L, Vanderkerken M, Van Gassen S, Plantinga M, 
et al. IRF8 transcription factor controls survival and function of terminally 
14
Minoda et al. Transcriptome of In Vivo Activated Human DC
Frontiers in Immunology | www.frontiersin.org October 2017 | Volume 8 | Article 1419
differentiated conventional and plasmacytoid dendritic cells, respectively. 
Immunity (2016) 45(3):626–40. doi:10.1016/j.immuni.2016.08.013 
43. Heidkamp GF, Sander J, Lehmann CHK, Heger L, Eissing N, Baranska A, 
et al. Human lymphoid organ dendritic cell identity is predominantly dictated 
by ontogeny, not tissue microenvironment. Sci Immunol (2016) 1:eaai7677. 
doi:10.1126/sciimmunol.aai7677 
44. Feuerer M, Beckhove P, Garbi N, Mahnke Y, Limmer A, Hommel M, et al. 
Bone marrow as a priming site for T-cell responses to blood-borne antigen. 
Nat Med (2003) 9(9):1151–7. doi:10.1038/nm914 
45. Milo I, Sapoznikov A, Kalchenko V, Tal O, Krauthgamer R, van Rooijen N, 
et  al. Dynamic imaging reveals promiscuous crosspresentation of blood-
borne antigens to naive CD8+ T  cells in the bone marrow. Blood (2013) 
122(2):193–208. doi:10.1182/blood-2012-01-401265 
46. Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A. Selected 
toll-like receptor agonist combinations synergistically trigger a T helper type 
1-polarizing program in dendritic cells. Nat Immunol (2005) 6(8):769–76. 
doi:10.1038/ni1223 
47. Tailor P, Tamura T, Kong HJ, Kubota T, Kubota M, Borghi P, et al. The feedback 
phase of type I interferon induction in dendritic cells requires interferon 
regulatory factor 8. Immunity (2007) 27(2):228–39. doi:10.1016/j.immuni. 
2007.06.009 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2017 Minoda, Virshup, Leal Rojas, Haigh, Wong, Miles, Wells and 
Radford. This is an open-access article distributed under the terms of the Creative 
Commons Attribution License (CC BY). The use, distribution or reproduction in 
other forums is permitted, provided the original author(s) or licensor are credited 
and that the original publication in this journal is cited, in accordance with accepted 
academic practice. No use, distribution or reproduction is permitted which does not 
comply with these terms.
